vs
Side-by-side financial comparison of PATHWARD FINANCIAL, INC. (CASH) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $173.1M, roughly 2.0× PATHWARD FINANCIAL, INC.). PATHWARD FINANCIAL, INC. runs the higher net margin — 20.3% vs 13.2%, a 7.1% gap on every dollar of revenue. On growth, PATHWARD FINANCIAL, INC. posted the faster year-over-year revenue change (-0.2% vs -2.7%). PATHWARD FINANCIAL, INC. produced more free cash flow last quarter ($104.1M vs $87.2M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -18.0%).
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CASH vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $173.1M | $339.0M |
| Net Profit | $35.2M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | 24.6% | 19.9% |
| Net Margin | 20.3% | 13.2% |
| Revenue YoY | -0.2% | -2.7% |
| Net Profit YoY | 11.9% | 19.3% |
| EPS (diluted) | $1.57 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $173.1M | $339.0M | ||
| Q3 25 | $186.7M | $327.3M | ||
| Q2 25 | $195.8M | $321.4M | ||
| Q1 25 | $274.8M | $330.6M | ||
| Q4 24 | $182.6M | $348.5M | ||
| Q3 24 | $179.5M | $345.5M | ||
| Q2 24 | $188.6M | $336.2M | ||
| Q1 24 | $257.6M | — |
| Q4 25 | $35.2M | $44.7M | ||
| Q3 25 | $38.8M | $38.7M | ||
| Q2 25 | $42.1M | $34.0M | ||
| Q1 25 | $75.0M | $58.0M | ||
| Q4 24 | $30.0M | $37.5M | ||
| Q3 24 | $33.5M | $33.8M | ||
| Q2 24 | $44.9M | $38.4M | ||
| Q1 24 | $69.9M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% | ||
| Q1 24 | — | — |
| Q4 25 | 24.6% | 19.9% | ||
| Q3 25 | 25.9% | 17.9% | ||
| Q2 25 | 24.1% | 16.8% | ||
| Q1 25 | 33.2% | 21.6% | ||
| Q4 24 | 19.8% | 16.9% | ||
| Q3 24 | 20.9% | 15.0% | ||
| Q2 24 | 27.1% | 11.8% | ||
| Q1 24 | 33.8% | — |
| Q4 25 | 20.3% | 13.2% | ||
| Q3 25 | 20.8% | 11.8% | ||
| Q2 25 | 21.5% | 10.6% | ||
| Q1 25 | 27.3% | 17.5% | ||
| Q4 24 | 16.4% | 10.8% | ||
| Q3 24 | 18.7% | 9.8% | ||
| Q2 24 | 23.8% | 11.4% | ||
| Q1 24 | 27.1% | — |
| Q4 25 | $1.57 | $0.95 | ||
| Q3 25 | $1.69 | $0.81 | ||
| Q2 25 | $1.81 | $0.70 | ||
| Q1 25 | $3.14 | $1.17 | ||
| Q4 24 | $1.23 | $0.74 | ||
| Q3 24 | $1.34 | $0.66 | ||
| Q2 24 | $1.78 | $0.74 | ||
| Q1 24 | $2.74 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $331.2M | $363.4M |
| Total DebtLower is stronger | $33.5M | $1.2B |
| Stockholders' EquityBook value | $854.5M | $911.5M |
| Total Assets | $7.6B | $2.5B |
| Debt / EquityLower = less leverage | 0.04× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $331.2M | $363.4M | ||
| Q3 25 | $120.6M | $296.4M | ||
| Q2 25 | $258.3M | $292.9M | ||
| Q1 25 | $254.2M | $306.8M | ||
| Q4 24 | $597.4M | $320.8M | ||
| Q3 24 | $158.3M | $299.3M | ||
| Q2 24 | $298.9M | $344.4M | ||
| Q1 24 | $347.9M | — |
| Q4 25 | $33.5M | $1.2B | ||
| Q3 25 | $33.5M | $1.2B | ||
| Q2 25 | $33.4M | $1.2B | ||
| Q1 25 | $33.4M | $1.2B | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $33.4M | — |
| Q4 25 | $854.5M | $911.5M | ||
| Q3 25 | $858.0M | $849.2M | ||
| Q2 25 | $819.0M | $882.3M | ||
| Q1 25 | $814.7M | $820.8M | ||
| Q4 24 | $758.3M | $906.9M | ||
| Q3 24 | $822.5M | $878.9M | ||
| Q2 24 | $748.4M | $905.4M | ||
| Q1 24 | $719.5M | — |
| Q4 25 | $7.6B | $2.5B | ||
| Q3 25 | $7.2B | $2.4B | ||
| Q2 25 | $7.2B | $2.5B | ||
| Q1 25 | $7.0B | $2.5B | ||
| Q4 24 | $7.6B | $2.5B | ||
| Q3 24 | $7.5B | $2.5B | ||
| Q2 24 | $7.5B | $2.5B | ||
| Q1 24 | $7.4B | — |
| Q4 25 | 0.04× | 1.34× | ||
| Q3 25 | 0.04× | 1.44× | ||
| Q2 25 | 0.04× | 1.39× | ||
| Q1 25 | 0.04× | 1.49× | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.05× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.3M | $93.6M |
| Free Cash FlowOCF − Capex | $104.1M | $87.2M |
| FCF MarginFCF / Revenue | 60.1% | 25.7% |
| Capex IntensityCapex / Revenue | 2.4% | 1.9% |
| Cash ConversionOCF / Net Profit | 3.08× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $616.8M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.3M | $93.6M | ||
| Q3 25 | $303.7M | $111.3M | ||
| Q2 25 | $30.4M | $17.4M | ||
| Q1 25 | $188.3M | $116.6M | ||
| Q4 24 | $-71.7M | $43.8M | ||
| Q3 24 | $143.1M | $48.8M | ||
| Q2 24 | $113.2M | $-27.4M | ||
| Q1 24 | $203.0M | — |
| Q4 25 | $104.1M | $87.2M | ||
| Q3 25 | $300.3M | $106.3M | ||
| Q2 25 | $27.7M | $13.6M | ||
| Q1 25 | $184.7M | $100.9M | ||
| Q4 24 | $-73.8M | $35.2M | ||
| Q3 24 | $138.8M | $39.4M | ||
| Q2 24 | $111.0M | $-33.1M | ||
| Q1 24 | $201.3M | — |
| Q4 25 | 60.1% | 25.7% | ||
| Q3 25 | 160.9% | 32.5% | ||
| Q2 25 | 14.1% | 4.2% | ||
| Q1 25 | 67.2% | 30.5% | ||
| Q4 24 | -40.4% | 10.1% | ||
| Q3 24 | 77.3% | 11.4% | ||
| Q2 24 | 58.8% | -9.8% | ||
| Q1 24 | 78.1% | — |
| Q4 25 | 2.4% | 1.9% | ||
| Q3 25 | 1.8% | 1.5% | ||
| Q2 25 | 1.4% | 1.2% | ||
| Q1 25 | 1.3% | 4.7% | ||
| Q4 24 | 1.1% | 2.5% | ||
| Q3 24 | 2.4% | 2.7% | ||
| Q2 24 | 1.2% | 1.7% | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 3.08× | 2.09× | ||
| Q3 25 | 7.83× | 2.88× | ||
| Q2 25 | 0.72× | 0.51× | ||
| Q1 25 | 2.51× | 2.01× | ||
| Q4 24 | -2.39× | 1.17× | ||
| Q3 24 | 4.27× | 1.44× | ||
| Q2 24 | 2.52× | -0.71× | ||
| Q1 24 | 2.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CASH
| Consumer | $103.0M | 59% |
| Payment Card And Deposit Fees | $30.1M | 17% |
| Other | $24.2M | 14% |
| Rental Income | $11.6M | 7% |
| Commercial | $4.2M | 2% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
